Yuyu Pharma (000220) - Net Assets

Latest as of September 2025: ₩139.10 Billion KRW ≈ $94.26 Million USD

Based on the latest financial reports, Yuyu Pharma (000220) has net assets worth ₩139.10 Billion KRW (≈ $94.26 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩202.42 Billion ≈ $137.18 Million USD) and total liabilities (₩63.32 Billion ≈ $42.91 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 000220 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩139.10 Billion
% of Total Assets	68.72%
Annual Growth Rate	5.51%
5-Year Change	15.4%
10-Year Change	83.18%
Growth Volatility	8.05

Yuyu Pharma - Net Assets Trend (2011–2024)

This chart illustrates how Yuyu Pharma's net assets have evolved over time, based on quarterly financial data. Also explore Yuyu Pharma balance sheet assets for the complete picture of this company's asset base.

Annual Net Assets for Yuyu Pharma (2011–2024)

The table below shows the annual net assets of Yuyu Pharma from 2011 to 2024. For live valuation and market cap data, see how much is Yuyu Pharma worth.

Year	Net Assets	Change
2024-12-31	₩135.06 Billion ≈ $91.53 Million	+12.22%
2023-12-31	₩120.36 Billion ≈ $81.56 Million	-2.45%
2022-12-31	₩123.37 Billion ≈ $83.61 Million	-4.13%
2021-12-31	₩128.69 Billion ≈ $87.21 Million	+9.95%
2020-12-31	₩117.04 Billion ≈ $79.31 Million	+29.26%
2019-12-31	₩90.54 Billion ≈ $61.36 Million	+4.23%
2018-12-31	₩86.87 Billion ≈ $58.87 Million	+4.88%
2017-12-31	₩82.83 Billion ≈ $56.14 Million	+5.80%
2016-12-31	₩78.29 Billion ≈ $53.06 Million	+6.19%
2015-12-31	₩73.73 Billion ≈ $49.97 Million	+3.14%
2014-12-31	₩71.49 Billion ≈ $48.45 Million	-1.09%
2013-12-31	₩72.28 Billion ≈ $48.98 Million	+3.99%
2012-12-31	₩69.50 Billion ≈ $47.10 Million	+3.38%
2011-12-31	₩67.23 Billion ≈ $45.56 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Yuyu Pharma's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 2578947719000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	₩25.79 Billion	20.59%
Other Components	₩99.44 Billion	79.41%
Total Equity	₩125.23 Billion	100.00%

Yuyu Pharma Competitors by Market Cap

The table below lists competitors of Yuyu Pharma ranked by their market capitalization.

Company	Market Cap
Bo Lak KO:002760	$46.56 Million
DONGJIANG ENVIRONMENTAL H F:DGN	$46.56 Million
Rapala VMC Oyj HE:RAP1V	$46.59 Million
CZR Resources Ltd AU:CZR	$46.59 Million
Charnic Capital Tbk PT JK:NICK	$46.55 Million
NexLiving Communities Inc V:NXLV	$46.54 Million
Boreo Oyj HE:BOREO	$46.51 Million
Plutus Financial Group Limited Ordinary Shares NASDAQ:PLUT	$46.51 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Yuyu Pharma's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 112,187,629,250 to 125,231,958,120, a change of 13,044,328,870 (11.6%).
Net income of 8,720,350,790 contributed positively to equity growth.
Other factors increased equity by 4,323,978,080.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	₩8.72 Billion	+6.96%
Other Changes	₩4.32 Billion	+3.45%
Total Change	₩-	11.63%

Book Value vs Market Value Analysis

This analysis compares Yuyu Pharma's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.55x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has increased from 0.31x to 0.55x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	₩13510.11	₩4245.00	x
2017-12-31	₩6921.45	₩4245.00	x
2018-12-31	₩7320.57	₩4245.00	x
2019-12-31	₩7543.57	₩4245.00	x
2020-12-31	₩7666.18	₩4245.00	x
2021-12-31	₩7461.74	₩4245.00	x
2022-12-31	₩7144.32	₩4245.00	x
2023-12-31	₩6932.58	₩4245.00	x
2024-12-31	₩7738.64	₩4245.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Yuyu Pharma utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 6.96%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 6.55%
• Asset Turnover: 0.64x
• Equity Multiplier: 1.66x
Recent ROE (6.96%) is above the historical average (1.10%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2011	2.19%	2.51%	0.66x	1.32x	₩-5.25 Billion
2012	3.97%	4.45%	0.70x	1.28x	₩-4.18 Billion
2013	2.28%	2.63%	0.64x	1.35x	₩-5.51 Billion
2014	-10.60%	-11.89%	0.62x	1.44x	₩-14.51 Billion
2015	-0.35%	-0.36%	0.67x	1.46x	₩-7.41 Billion
2016	7.63%	8.22%	0.64x	1.44x	₩-1.83 Billion
2017	5.54%	7.23%	0.52x	1.48x	₩-3.65 Billion
2018	4.69%	4.84%	0.61x	1.58x	₩-4.56 Billion
2019	5.32%	5.20%	0.66x	1.55x	₩-4.15 Billion
2020	1.12%	1.31%	0.63x	1.35x	₩-10.15 Billion
2021	-1.78%	-1.91%	0.60x	1.55x	₩-14.64 Billion
2022	-5.13%	-4.31%	0.71x	1.67x	₩-17.67 Billion
2023	-6.40%	-5.23%	0.69x	1.77x	₩-18.40 Billion
2024	6.96%	6.55%	0.64x	1.66x	₩-3.80 Billion

Industry Comparison

This section compares Yuyu Pharma's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $438,266,906,394
Average return on equity (ROE) among peers: 0.44%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Yuyu Pharma (000220)	₩139.10 Billion	2.19%	0.46x	$46.55 Million
Dongwha Pharm.Co.Ltd (000020)	$252.93 Billion	10.38%	0.28x	$113.83 Million
Yuhan Corp. (000100)	$407.93 Billion	10.79%	0.55x	$4.57 Billion
Yuhan Corp Preferred (000105)	$1.65 Trillion	2.42%	0.28x	$59.61 Million
Yuyu Pharma Inc (000225)	$117.04 Billion	1.10%	0.32x	$17.67 Million
Yuyu Pharma Inc (000227)	$78.29 Billion	7.52%	0.42x	$42.93 Million
Ildong Holdings Co Ltd (000230)	$169.10 Billion	-60.53%	4.10x	$76.14 Million
Samil Pharm (000520)	$127.83 Billion	1.30%	1.90x	$127.90 Million
Donga Socio Holdings (000640)	$875.86 Billion	17.02%	0.60x	$427.15 Million
Jw Pharmac (001060)	$265.44 Billion	13.94%	1.43x	$476.78 Million

About Yuyu Pharma

KO:000220 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$46.55 Million

₩68.70 Billion KRW

Market Cap Rank

#22149 Global

#1482 in Korea

Share Price

₩4245.00

Change (1 day)

-1.05%

52-Week Range

₩4055.00 - ₩4770.00

All Time High

₩16106.03